Drug General Information
Drug ID	D01UUD
Former ID	DNCL003130
Drug Name	Pitolisant
Drug Type	Small molecular drug
Indication	Schizophrenia [ICD9: 295; ICD10:F20]		Phase 3	[1]
Company	Bioprojet; Ferrer
Structure		Download 2D MOL 3D MOL
Formula	C17H26ClNO
Canonical SMILES	C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
InChI	1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
InChIKey	NNACHAUCXXVJSP-UHFFFAOYSA-N
PubChem Compound ID	9948102
PubChem Substance ID	14922700, 24219069, 57373865, 76236908, 103590504, 104102226, 134346295, 135267132, 136061457, 137014530, 139406634, 152258405, 160647242, 162223312, 162510281, 185985203, 198942557, 202535639, 224056376, 226489682, 252480498
Target and Pathway
Target(s)	Histamine H3 receptor	Target Info	Agonist	[2]
KEGG Pathway	Neuroactive ligand-receptor interaction
Reactome	Histamine receptors
	G alpha (i) signalling events
WikiPathways	Monoamine Transport
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
REF 1	ClinicalTrials.gov (NCT01800045) Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP). U.S. National Institutes of Health.
REF 2	Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med. 2014 Jun;15(6):681-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.